Simcere Pharmaceutical Group and JW Pharmaceutical announced a collaboration and exclusive license agreement for anti-gout drug candidate URC-102 in China (including Chinese Hongkong & Macao). Simcere will be responsible for the clinical research, registration and commercialization of URC-102 in China. Under the terms of the agreement, JWP will receive upfront payment, milestones and sales royalties from commercialization in China.